EGFR and cancer: Furthermore, the conjugation of the aptamer specific for EGFR with the immunomodulatory 10_12 mAb allowed also for the efficient redirection and activation of T cells against cancer cells, thus dramatically enhancing the cytotoxicity of the two conjugated partners.